Wall Street Zen upgraded shares of Establishment Labs (NASDAQ:ESTA - Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.
Other equities research analysts have also recently issued research reports about the company. Stephens reissued an "overweight" rating and set a $52.00 target price on shares of Establishment Labs in a research note on Thursday, March 6th. Needham & Company LLC reissued a "buy" rating and set a $48.00 target price on shares of Establishment Labs in a research note on Friday. Finally, BTIG Research began coverage on Establishment Labs in a research note on Friday, May 16th. They set a "buy" rating and a $62.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $52.40.
Get Our Latest Research Report on ESTA
Establishment Labs Price Performance
Shares of NASDAQ:ESTA traded up $0.32 during midday trading on Friday, hitting $37.44. The company had a trading volume of 659,994 shares, compared to its average volume of 476,529. Establishment Labs has a twelve month low of $26.56 and a twelve month high of $52.41. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -14.51 and a beta of 0.74. The business's 50-day simple moving average is $33.99 and its 200-day simple moving average is $37.36.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%. The firm had revenue of $41.38 million during the quarter, compared to analysts' expectations of $41.15 million. During the same quarter last year, the firm earned ($0.58) earnings per share. The business's revenue for the quarter was up 11.3% on a year-over-year basis. On average, research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of ESTA. Toronto Dominion Bank purchased a new position in Establishment Labs in the fourth quarter valued at $24,879,000. Brown Advisory Inc. boosted its holdings in Establishment Labs by 23.1% in the fourth quarter. Brown Advisory Inc. now owns 2,338,369 shares of the company's stock valued at $107,729,000 after purchasing an additional 438,057 shares during the period. Capital Research Global Investors boosted its holdings in Establishment Labs by 29.3% in the fourth quarter. Capital Research Global Investors now owns 1,911,525 shares of the company's stock valued at $88,064,000 after purchasing an additional 433,484 shares during the period. Voya Investment Management LLC boosted its holdings in Establishment Labs by 7,249.5% in the fourth quarter. Voya Investment Management LLC now owns 408,262 shares of the company's stock valued at $18,809,000 after purchasing an additional 402,707 shares during the period. Finally, Millennium Management LLC boosted its holdings in Establishment Labs by 96.9% in the fourth quarter. Millennium Management LLC now owns 711,691 shares of the company's stock valued at $32,788,000 after purchasing an additional 350,213 shares during the period. 72.91% of the stock is currently owned by hedge funds and other institutional investors.
About Establishment Labs
(
Get Free Report)
Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.
Further Reading
Before you consider Establishment Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Establishment Labs wasn't on the list.
While Establishment Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
